Vectura Group appoints Juliet Thompson to its Board as Independent Non-Executive Director

– UK, Chippenham – Vectura Group plc (LSE:VEC), an industry leading device and formulation business for inhaled airways products, is pleased to announce the appointment of Juliet Thompson as an Independent Non-Executive Director of the Company with effect from 1 December 2017. Upon appointment, Juliet will also become a member of the Audit Committee.

Juliet has spent approximately 20 years working as an investment banker and strategic advisor to healthcare companies in Europe. She has a strong track record of advising companies on corporate strategy across numerous transactions. She is a member of the Institute of Chartered Accountants in England and Wales (ACA) and holds a BSc degree in Economics from the University of Bristol. Her experience includes senior roles (Managing Director, Head of Corporate Finance and Partner) at Stifel Financial Corp, Nomura Code Securities and WestLB Panmure. She also worked at ICI PLC, Deloitte and Touche and HM Treasury.

She is currently a Non-Executive Director of Nexstim plc, a Nasdaq-listed Finnish medical technology company, Novacyt S.A., a French-based company whose shares are admitted to trade on AIM, and GI Dynamics, Inc a US headquartered, Australian stock exchange listed company. Juliet chairs the Audit Committee of each of these three companies. She is also Non-Executive Chair of the Board of Premier Veterinary Group plc, an LSE-listed company.

Bruno Angelici, Chairman of Vectura: “I am delighted to welcome Juliet to Vectura. Her extensive experience both of the banking and industry will bring important insight to Board discussions, as well as supplementing and strengthening the existing skills and experience of the Board. We look forward to working with her.”

About Vectura

Vectura, listed on the London Stock Exchange (LSE: VEC), is an industry leading device and formulation business for inhaled airways products offering a uniquely integrated inhaled drug delivery platform. With our extensive range of device and formulation technologies, integrated capabilities and collaborations, we are a leader in the development of inhalation products, increasing our ability to help patients suffering from respiratory diseases.

Vectura has eight inhaled, four non-inhaled and ten oral products marketed by partners with growing global royalty streams, and a portfolio of drugs in clinical development, a number of which have licence agreements with several global pharmaceutical and biotechnology companies including Hikma, Novartis, Sandoz, Mundipharma, Kyorin, Baxter, GSK, UCB, Ablynx, Grifols, Bayer, Chiesi, Almirall, Janssen, and Tianjin KingYork.

For more information :

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.